Page 75 - Read Online

Jayachandran et al. Hepatoma Res 2020;6:8 I http://dx.doi.org/10.20517/2394-5079.2019.35 Page 13 of 14

Mediterranean Basin. Liver 2001;21:233-6.
77. Constantine CC, Gurrin LC, McLaren CE, Bahlo M, Anderson GJ, et al. SNP selection for genes of iron metabolism in a study of
genetic modifiers of hemochromatosis. BMC Med Genet 2008;9:18.
78. Racchi O, Mangerini R, Rapezzi D, Gaetani GF, Nobile MT, et al. Mutations of the HFE gene and the risk of hepatocellular
carcinoma. Blood Cells Mol Dis 1999;25:350-3.
79. Kew MC. Hepatic iron overload and hepatocellular carcinoma. Liver Cancer 2014;3:31-40.
80. Shen Y, Li X, Zhao B, Xue Y, Wang S, et al. Iron metabolism gene expression and prognostic features of hepatocellular carcinoma. J
Cell Biochem 2018;119:9178-204.
81. Pantopoulos K. Inherited disorders of iron overload. Front Nutr 2018;5:103.
82. Worthen CA, Enns CA. The role of hepatic transferrin receptor 2 in the regulation of iron homeostasis in the body. Front Pharmacol
2014;5:34.
83. Andrews NC. Disorders of iron metabolism. N Engl J Med 1999;341:1986-95.
84. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and
inducing its internalization. Science 2004;306:2090-3.
85. West AP, Bennett MJ, Sellers VM, Andrews NC, Enns CA, et al. Comparison of the interactions of transferrin receptor and transferrin
receptor 2 with transferrin and the hereditary hemochromatosis protein HFE. J Biol Chem 2000;275:38135-8.
86. Lesbordes-Brion JC, Viatte L, Bennoun M, Lou DQ, Ramey G, et al. Targeted disruption of the hepcidin 1 gene results in severe
hemochromatosis. Blood 2006;108:1402-5.
87. Wu XG, Wang Y, Wu Q, Cheng WH, Liu W, et al. HFE interacts with the BMP type I receptor ALK3 to regulate hepcidin expression.
Blood 2014;124:1335-43.
88. Gao J, Chen J, Kramer M, Tsukamoto H, Zhang AS, et al. Interaction of the hereditary hemochromatosis protein HFE with transferrin
receptor 2 is required for transferrin-induced hepcidin expression. Cell Metab 2009;9:217-27.
89. Zacharski LR, Ornstein DL, Woloshin S, Schwartz LM. Association of age, sex, and race with body iron stores in adults: analysis of
NHANES III data. Am Heart J 2000;140:98-104.
90. Asare GA, Paterson AC, Kew MC, Khan S, Mossanda KS. Iron-free neoplastic nodules and hepatocellular carcinoma without cirrhosis
in Wistar rats fed a diet high in iron. J Pathol 2006;208:82-90.
91. Ioannou GN, Kowdley KV. Iron, HFE mutations, and hepatocellular carcinoma: is hepatic iron a carcinogen? Clin Gastroenterol
Hepatol 2003;1:246-8.
92. Ramm GA, Crawford DH, Powell LW, Walker NI, Fletcher LM, et al. Hepatic stellate cell activation in genetic haemochromatosis.
Lobular distribution, effect of increasing hepatic iron and response to phlebotomy. J Hepatol 1997;26:584-92.
93. Yu Y, Kovacevic Z, Richardson DR. Tuning cell cycle regulation with an iron key. Cell Cycle 2007;6:1982-94.
94. Toyokuni S. Role of iron in carcinogenesis: cancer as a ferrotoxic disease. Cancer Sci 2009;100:9-16.
95. Fargion S, Valenti L, Fracanzani AL. Role of iron in hepatocellular carcinoma. Clin Liver Dis (Hoboken) 2014;3:108-10.
96. Moukhadder HM, Halawi R, Cappellini MD, Taher AT. Hepatocellular carcinoma as an emerging morbidity in the thalassemia
syndromes: a comprehensive review. Cancer 2017;123:751-8.
97. Marshall A, Lukk M, Kutter C, Davies S, Alexander G, Odom DT. Global gene expression profiling reveals SPINK1 as a potential
hepatocellular carcinoma marker. PLoS One 2013;8:e59459.
98. Miyanishi K, Tanaka S, Sakamoto H, Kato J. The role of iron in hepatic inflammation and hepatocellular carcinoma. Free Radic Biol
Med 2019;133:200-5.
99. Muto Y, Moroishi T, Ichihara K, Nishiyama M, Shimizu H, et al. Disruption of FBXL5-mediated cellular iron homeostasis promotes
liver carcinogenesis. J Exp Med 2019;216:950-65.
100. Hussain SP, Hollstein MH, Harris CC. p53 tumor suppressor gene: at the crossroads of molecular carcinogenesis, molecular
epidemiology, and human risk assessment. Ann N Y Acad Sci 2000;919:79-85.
101. Ichiba M, Maeta Y, Mukoyama T, Saeki T, Yasui S, et al. Expression of 8-hydroxy-2’-deoxyguanosine in chronic liver disease and
hepatocellular carcinoma. Liver Int 2003;23:338-45.
102. Valerio LG, Petersen DR. Characterization of hepatic iron overload following dietary administration of dicyclopentadienyl iron
(Ferrocene) to mice: cellular, biochemical, and molecular aspects. Exp Mol Pathol 2000;68:1-12.
103. Kowdley KV. Iron, hemochromatosis, and hepatocellular carcinoma. Gastroenterology 2004;127:S79-86.
104. Olynyk JK, St Pierre TG, Britton RS, Brunt EM, Bacon BR. Duration of hepatic iron exposure increases the risk of significant fibrosis
in hereditary hemochromatosis: a new role for magnetic resonance imaging. Am J Gastroenterol 2005;100:837-41.
105. Cabantchik ZI, Breuer W, Zanninelli G, Cianciulli P. LPI-labile plasma iron in iron overload. Best Pract Res Clin Haematol
2005;18:277-87.
106. Asare GA, Bronz M, Naidoo V, Kew MC. Synergistic interaction between excess hepatic iron and alcohol ingestion in hepatic
mutagenesis. Toxicology 2008;254:11-8.
107. Nahon P, Sutton A, Pessayre D, Rufat P, Charnaux N, et al. Do genetic variations in antioxidant enzymes influence the course of
hereditary hemochromatosis? Antioxid Redox Signal 2011;15:31-8.
108. Houglum K, Bedossa P, Chojkier M. TGF-beta and collagen-alpha 1 (I) gene expression are increased in hepatic acinar zone 1 of rats
with iron overload. Am J Physiol 1994;267:G908-13.
109. Wallace DF, Subramaniam VN. Co-factors in liver disease: the role of HFE-related hereditary hemochromatosis and iron. Biochim
Biophys Acta 2009;1790:663-70.
110. Hann HW, Stahlhut MW, Hann CL. Effect of iron and desferoxamine on cell growth and in vitro ferritin synthesis in human hepatoma
cell lines. Hepatology 1990;11:566-9.
111. Shen Y, Li X, Su Y, Badshah SA, Zhang B, et al. Downregulation contributes to aggressive hepatocellular carcinoma via mechanism